ConductScience.org, home

Gene · 4065

LY75: lymphocyte antigen 75

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. LY75: lymphocyte antigen 75. Genes, record 4065. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4065

On this page

Gene

Symbol
LY75
HGNC
Name
lymphocyte antigen 75
HGNC
NCBI Gene ID
4065
NCBI Gene
HGNC ID
HGNC:6729
HGNC
Ensembl
ENSG00000054219
NCBI Gene
Aliases
CD205, CLEC13B, DEC-205, GP200-MR6, LY-75
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
O60449Lymphocyte antigen 751,7224Ensembl, GeneID, HGNC

Source UniProt

Patents67

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2025172069 A2025-11-2078O60449Espacenet
EP 4650780 A22025-11-192229O60449Espacenet
EP 4641201 A22025-10-291805O60449Espacenet
EP 4641202 A22025-10-29109O60449Espacenet
EP 4641203 A22025-10-2969O60449Espacenet
JP 2025529142 A2025-09-042500O60449Espacenet
US 12371689 B22025-07-292500O60449Espacenet
JP 2025517967 A2025-06-1269O60449Espacenet
JP 2025517969 A2025-06-121805O60449Espacenet
JP 2025517970 A2025-06-122229O60449Espacenet

1 to 10 of 67

See all 67 patents

Drugs1

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismAction
RASDEGAFUSP ALFACHEMBL4297923Lymphocyte antigen 75 binding agentBINDING AGENT

Source ChEMBL

Trials5

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT02661100RASDEGAFUSP ALFAPHASE1/PHASE2ClinicalTrials.gov
NCT02495636RASDEGAFUSP ALFAPHASE2ClinicalTrials.gov
NCT02413827RASDEGAFUSP ALFAPHASE1/PHASE2ClinicalTrials.gov
NCT02129075RASDEGAFUSP ALFAPHASE22021-11-16ClinicalTrials.gov
NCT00948961RASDEGAFUSP ALFAPHASE1/PHASE2ClinicalTrials.gov

NIH grants1,428

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleLY75 papersNewest fiscal year
R01CA124515Crosstalk between butyrophilins and gamma delta T cells in human cancer72025
P30CA034196Cancer Center Support (CORE) Grant62025
P30CA016056Roswell Park Cancer Center Support Grant52025
P30CA016087Cancer Center Support Grant52025
P30CA047904Cancer Center Support Grant52025
P30DK020541NYR-Diabetes Research Center (NYR-DRC)52025
P30DK034854Integrated Epithelial and Muscosal Biology42025
P51OD011132Emory National Primate Research Center42025
UL1TR001863Yale Clinical and Translational Science Award42025
P30CA013330Cancer Center Support Grant32025

1 to 10 of 1,428Source NIH's project files

See all 1,428 nih grants

Papers1,798

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Improved protocol for isolation and characterization of human thymic epithelial cells.J Immunol Methods202642679888PubTator, text miningPubMed
Risk factors of clonal hematopoiesis of indeterminate potential.Clin Med (Lond)202642570703PubTator, text miningPubMed
Why is the antigen uptake receptor DEC205 (CD205) of interest?Expert Rev Clin Immunol202642305100PubTator, text miningPubMed
Metabolic Tagging of Tumour Extracellular Vesicles for Targeted Modulation of Dendritic Cells.J Extracell Vesicles202642209448PubTator, text miningPubMed
A multimodal atlas for immunotherapeutic targeting of AML surface heterogeneity.iScience202641959675PubTator, text miningPubMed
Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives.Vaccines (Basel)202641893758PubTator, text miningPubMed
Tim-3-targeted vaccines overcome tumor immunosuppression and reduce cDC1 dependence to elicit potent anti-tumor immunity.Proc Natl Acad Sci U S A202641855265PubTator, text miningPubMed
Dual-Targeting mRNA Cancer Vaccines for Simultaneous Antigen Presentation in Dendritic and Tumor Cells.ACS Nano202641841891PubTator, text miningPubMed
Rational design of next-generation vaccine adjuvants: From molecular mechanisms to hybrid delivery platforms.Hum Vaccin Immunother202641837360PubTator, text miningPubMed
CD28-deficient mice are vulnerable to mouse papillomavirus MmuPV1 infection of the skin and mucosae.PLoS Pathog202641805718PubTator, text miningPubMed

1 to 10 of 1,798

See all 1,798 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/4065

GET https://conductscience.org/api/genes/v1/4065/patents?page=2